Pancreatic Cancer Clinical Trials in St. Petersburg, Florida

5 studies are recruiting for pancreatic cancer in St. Petersburg, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

    The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Florida Cancer Specialists - North, St. Petersburg, Florida
    Locations
    48 in total
    Run by
    Immuneering Corporation

    See if you can join NCT07562152 on ClinicalTrials.gov

  2. Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

    The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Florida Cancer Specialists, St. Petersburg, Florida
    Locations
    74 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT07252232 on ClinicalTrials.gov

  3. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Florida Cancer Specialists and Research Institute, St. Petersburg, Florida
    Locations
    39 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06465069 on ClinicalTrials.gov

  4. DESTINY-PANTUMOUR04

    This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world…

    Stage
    Not phased
    Ages
    18 to 130
    Site
    Research Site, St. Petersburg, Florida
    Locations
    18 in total
    Run by
    AstraZeneca

    See if you can join NCT07124000 on ClinicalTrials.gov

  5. A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

    The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Florida Cancer Specialists - North, St. Petersburg, Florida
    Locations
    28 in total
    Run by
    Jazz Pharmaceuticals

    See if you can join NCT06695845 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.